Gilead Sciences Inc

Latest stories

22h
CBS News
FDA approves first pill to treat all types of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all types of hepatitis C
CBS News / Posted 22 hours ago
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
46 related stories
23h
Jefferson City News Tribune
FDA approves first pill to treat all forms of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all forms of hepatitis C
Jefferson City News Tribune / Posted 23 hours ago
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
46 related stories
1d
Philly.com
FDA approves first pill to treat all forms of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all forms of hepatitis C
Philly.com / Posted yesterday
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
46 related stories
1d
The Signal
FDA approves first pill to treat all forms of hepatitis Cwith over $18 billion in global sales, according to IMS Health. Sovaldi ranked
FDA approves first pill to treat all forms of hepatitis C
The Signal / Posted yesterday
with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
46 related stories
1d
Orange County Register
FDA approves first pill to treat all forms of hepatitis Cin the world with over $18 billion in global sales, according to IMS Health. So
FDA approves first pill to treat all forms of hepatitis C
Orange County Register / Posted yesterday
in the world with over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, rose $4.06, or 5.2 percent, to $82.31 on T... Read more
46 related stories
1d
Silicon Valley
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
Silicon Valley / Posted yesterday
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
46 related stories
1d
WDIO Duluth
FDA Approves First Pill to Treat All Forms of Hepatitis C$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pu
FDA Approves First Pill to Treat All Forms of Hepatitis C
WDIO Duluth / Posted yesterday
$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $4.06, or 5.2 percent, to $82.31 on... Read more
46 related stories
1d
The Mercury News
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
The Mercury News / Posted yesterday
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
46 related stories
1d
Sun-Sentinel
FDA approves first pill to treat all forms of hepatitis C$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pu
FDA approves first pill to treat all forms of hepatitis C
Sun-Sentinel / Posted yesterday
$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon... Read more
46 related stories
1d
The Columbian
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
The Columbian / Posted yesterday
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
46 related stories
1d
Providence Business News
U.S. stocks rebound as worries ease after two-day Brexit selloffUtilities, raw materials and consumer staples were little changed. Biotechnolo
U.S. stocks rebound as worries ease after two-day Brexit selloff
Providence Business News / Posted yesterday
Utilities, raw materials and consumer staples were little changed. Biotechnology shares led the rally in health-care, with Gilead Sciences Inc. jumping 4 percent, the most in almost five months. Regulators approved Gilead’s hepatitis C drug for all... Read more
13 related stories
1d
The Record Searchlight
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
The Record Searchlight / Posted yesterday
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
46 related stories
1d
Your Hometown Lima Stations
FDA approves first pill to treat all forms of hepatitis C$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pu
FDA approves first pill to treat all forms of hepatitis C
Your Hometown Lima Stations / Posted yesterday
$18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon... Read more
46 related stories
1d
Market Watch
Gilead receives approval for cheaper hepatitis C drugGilead Sciences Inc. received U.S. Food and Drug Administration approval for it
Gilead receives approval for cheaper hepatitis C drug
Market Watch / Posted yesterday
Gilead Sciences Inc. received U.S. Food and Drug Administration approval for its Epclusa hepatitis C combination drug and priced the treatment below its older drugs for the disease. Shares of the Foster City, Calif., company, which dominates the... Read more
46 related stories
1d
WFTV 9 Orlando
FDA approves first pill to treat all forms of hepatitis Cover $18 billion in global sales, according to IMS Health. Sovaldi ranked eight
FDA approves first pill to treat all forms of hepatitis C
WFTV 9 Orlando / Posted yesterday
over $18 billion in global sales, according to IMS Health. Sovaldi ranked eighth, pulling in $6.6 billion in sales. Shares of Gilead Sciences Inc., which is based in Foster City, California, rose $3.16, or 4 percent, to $81.41 in afternoon tra... Read more
46 related stories
1d
Los Angeles Times
FDA approves first pill to treat all forms of hepatitis Chave reshaped treatment of the liver-destroying virus. The Food and Drug Admin
FDA approves first pill to treat all forms of hepatitis C
Los Angeles Times / Posted yesterday
have reshaped treatment of the liver-destroying virus. The Food and Drug Administration approved the combination pill from Gilead Sciences Inc. for patients with and without liver damage. The agency has approved a number of hepatitis C drugs in... Read more
46 related stories
2d
Boston Globe
Harvard Pilgrim adds new drugs under ‘pay-for-performance dealslast year, it became the first regional health insurer to negotiate a discount
Harvard Pilgrim adds new drugs under ‘pay-for-performance deals
Boston Globe / Posted 2 days ago
last year, it became the first regional health insurer to negotiate a discount of a costly hepatitis C drug made by Gilead Sciences Inc. That contract, which was not outcomes-based, has saved Harvard Pilgrim and its customers between $5... Read more
7d
FOX Business
Can These Upstarts Knock Gilead Sciences Off Its Perch?Image source: Getty Images. Continue Reading Below Gilead Sciences is about t
Can These Upstarts Knock Gilead Sciences Off Its Perch?
FOX Business / Posted 7 days ago
Image source: Getty Images. Continue Reading Below Gilead Sciences is about to find out if the FDA will approve its latest hepatitis C drug, and if it does, then that approval will solidify Gilead Sciences as the Goliath in the hepatitis C... Read more
3 related stories
13d
The Globe and Mail
Whether tainted blood or thalidomide, be wary of government’s vague promisesa cure for hepatitis C. In clinical trials, cure rates hover above 95 per cent.
Whether tainted blood or thalidomide, be wary of government’s vague promises
The Globe and Mail / Posted 13 days ago
a cure for hepatitis C. In clinical trials, cure rates hover above 95 per cent. But these drugs – Sovaldi and Harvoni from Gilead Sciences Inc. and Holkira Pak from AbbVie Canada – are expensive (in the range of $55,000) and not necessarily covered... Read more
2 related stories
15d
FOX Business
Infinity Pharmaceuticals Stock Plunges Toward Record Low After Drug Study DisappointsRBC Capital analyst Michael Yee said the response rate of 46% was below the 54%
Infinity Pharmaceuticals Stock Plunges Toward Record Low After Drug Study Disappoints
FOX Business / Posted 15 days ago
RBC Capital analyst Michael Yee said the response rate of 46% was below the 54% response rate of a rival treatment from Gilead Sciences Inc. , which suffers from lackluster sales. Infinity said its restructuring will include closing down its... Read more
2 related stories
15d
FOX Business
Infinity Pharmaceuticals Stock Plunges Toward Record Low After Drug Study DisappointsRBC Capital analyst Michael Yee said the response rate of 46% was below the 54%
Infinity Pharmaceuticals Stock Plunges Toward Record Low After Drug Study Disappoints
FOX Business / Posted 15 days ago
RBC Capital analyst Michael Yee said the response rate of 46% was below the 54% response rate of a rival treatment from Gilead Sciences Inc. , which suffers from lackluster sales. Infinity said its restructuring will include closing down its... Read more
2 related stories
15d
Market Watch
Infinity Pharmaceuticals stock plunges toward record low after drug study disappointsRBC Capital analyst Michael Yee said the response rate of 46% was below the 54%
Infinity Pharmaceuticals stock plunges toward record low after drug study disappoints
Market Watch / Posted 15 days ago
RBC Capital analyst Michael Yee said the response rate of 46% was below the 54% response rate of a rival treatment from Gilead Sciences Inc. GILD, -0.56% which suffers from lackluster sales. Infinity said its restructuring will include closing... Read more
2 related stories
16d
Business Wire
Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today
Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
Business Wire / Posted 16 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its corporate presentation will be webcast from the 36th Annual William Blair Growth Stock Conference in Chicago. Robin L. Washington, Gilead’s Executive... Read more
20d
Business Wire
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today
Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
Business Wire / Posted 20 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies 2016 Healthcare... Read more
22d
Business Wire
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) toda
Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
Business Wire / Posted 22 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief Scientific Officer, will participate in a fireside chat at the Goldman... Read more
22d
Market Watch
Judge throws out Merck’s $200 million verdict over GileadA federal judge has reversed a jury’s verdict that Gilead Sciences Inc. should
Judge throws out Merck’s $200 million verdict over Gilead
Market Watch / Posted 22 days ago
A federal judge has reversed a jury’s verdict that Gilead Sciences Inc. should pay $200 million to Merck & Co. in a drug-patent dispute, after the judge concluded Merck engaged in misconduct in its efforts to obtain patents for hepatitis C... Read more
7 related stories
22d
Business Insurance
Gilead escapes liability in patent fight with Merckon Monday found a pattern of misconduct by Merck & Co. including lying under oa
Gilead escapes liability in patent fight with Merck
Business Insurance / Posted 22 days ago
on Monday found a pattern of misconduct by Merck & Co. including lying under oath and other unethical practices, freeing Gilead Sciences Inc. from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C,... Read more
7 related stories
23d
Channel NewsAsia
Gilead escapes liability in hepatitis C patent fight with Merckon Monday found a pattern of misconduct by Merck & Co including lying under oat
Gilead escapes liability in hepatitis C patent fight with Merck
Channel NewsAsia / Posted 23 days ago
on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C,... Read more
7 related stories
23d
Channel NewsAsia
Gileads escapes liability in hepatitis C patent fight with Merckon Monday found a pattern of misconduct by Merck & Co including lying under oat
Gileads escapes liability in hepatitis C patent fight with Merck
Channel NewsAsia / Posted 23 days ago
on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck's patents with its lucrative treatments for hepatitis C,... Read more
7 related stories
23d
Boston Globe
Mass. emerges as a leader in efforts to rein in soaring drug pricesMark C. Montignyisproposing sweeping provisions to rein in drug prices. ■ Atto
Mass. emerges as a leader in efforts to rein in soaring drug prices
Boston Globe / Posted 23 days ago
Mark C. Montignyisproposing sweeping provisions to rein in drug prices. ■ Attorney General Maura Healey is pressing Gilead Sciences Inc. to cut the price of its hepatitis C treatments. ■ And a Boston watchdog group is leading the charge to... Read more
m
Business Wire
Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an inves
Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc.
Business Wire / Posted 1 months ago
NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Gilead Sciences Inc. (“Gilead Sciences” or the “Company”) (NASDAQ:GILD) concerning possible violations of federal securities laws. On May 6, 2016, Gilead... Read more
m
FOX Business
Gilead Sciences Inc. vs. Johnson & JohnsonImage source: Johnson & Johnson. They're two of the biggies in healthcare. Gil
Gilead Sciences Inc. vs. Johnson & Johnson
FOX Business / Posted 1 months ago
Image source: Johnson & Johnson. They're two of the biggies in healthcare. Gilead Sciences Inc. grew to become the largest biotech in the world over the last decade on the back of its HIV and hepatitis C franchises. Meanwhile, Johnson & Johnson has... Read more
8 related stories
m
FOX Business
Gilead Sciences Inc. vs. Johnson & JohnsonImage source: Johnson & Johnson. Continue Reading Below They're two of the bi
Gilead Sciences Inc. vs. Johnson & Johnson
FOX Business / Posted 1 months ago
Image source: Johnson & Johnson. Continue Reading Below They're two of the biggies in healthcare. Gilead Sciences Inc. grew to become the largest biotech in the world over the last decade on the back of its HIV and hepatitis C franchises.... Read more
8 related stories

People in this news